Lotyšsko - lotyština - Zāļu valsts aģentūra

galderma international, france - ivermektīns - krēms - 10 mg/g

Lotyšsko - lotyština - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - minoksidils - uz ādas lietojams šķīdums - 20 mg/ml

Lotyšsko - lotyština - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - minoksidils - uz ādas lietojams šķīdums - 50 mg/ml

Európska únia - lotyština - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatīts, atopisks - citi dermatoloģiski preparāti - staquis ir indicēts, lai ārstētu vieglas līdz vidēji atopiskā dermatīta pieaugušajiem un pediatrijas pacientiem no 2 gadu vecuma ar ≤ 40% ķermeņa virsmas (bsa) ietekmēt.

Lotyšsko - lotyština - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - minoksidils - uz ādas lietojams šķīdums - 50 mg/ml

Európska únia - lotyština - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabs - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Lotyšsko - lotyština - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - finasterīds - apvalkotā tablete - 1 mg

Európska únia - lotyština - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatīts, atopisks - citi dermatoloģiski preparāti - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Európska únia - lotyština - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatīts, atopisks - citi dermatoloģiski preparāti - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Európska únia - lotyština - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - citi dermatoloģiski preparāti - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.